SCHEMBL2074196

SCHEMBL2074196

Cc1[c][nH]c2cccc(O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.41
IMPDH1 P20839 1/20 0.41
HTR2A P28223 7/20 0.38
HTR2C P28335 6/20 0.38
HTR2B P41595 4/20 0.38
HTR1A P08908 2/20 0.36
DRD1 P21728 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
HTR1E P28566 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
HTR7 P34969 1/20 0.36
DRD3 P35462 1/20 0.36
HTR5A P47898 1/20 0.36
HTR6 P50406 1/20 0.36
TRPA1 O75762 2/20 0.35
MAPT P10636 2/20 0.35
THRB P10828 2/20 0.35
RECQL P46063 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407501 0.79 IMPDH2 (0.44) IMPDH2IMPDH1HTR2AHTR2CHTR2B
SCHEMBL1850720 0.79 GPR84 (0.41) HTR2AMAPTTSHRATMMEN1
SCHEMBL4694663 0.76 GAA (0.39) GAAALDH1A1MGAMSIMGAM2
SCHEMBL2073636 0.76 FFAR1 (0.39) HTR2AHTR2CHTR2BHTR1AHTR7
SCHEMBL2070937 0.73 KIF11 (0.40) TDP1TSHRALDH1A1
SCHEMBL2072979 0.73 ABCG2 (0.42) HTR2AHTR2CHTR2BHTR6MAPT
SCHEMBL2073080 0.69 HTR2A (0.43) HTR2AHTR2CHTR2BHTR1ADRD1
SCHEMBL10505940 0.68 GABRA1 (0.35) IMPDH2IMPDH1HTR2AHTR2CHTR2B
SCHEMBL3886120 0.66 IMPDH2 (0.71) IMPDH2IMPDH1HTR2AHTR2CHTR2B
SCHEMBL546371 0.66 CYP1A2 (0.42) MAPTHPGDALOX15TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828171-B1 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2014-03-12 EP disclosed
US-7863294-B2 Heterocycle derivatives as histone deacetylase (HDAC) inhibitors INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-01-04 US disclosed
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
EP-1828171-A2 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2007-09-05 EP disclosed
WO-2006061638-A2 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors HDAC1, HDAC5, HDAC11 IMPDH2 2557/4885IMPDH1 1890/4885HTR2A 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.